Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin in Advanced Germ-cell Tumors
NCT01851200Phase 2Completed
- Sponsor
- Michelangelo Foundation
- Start
- May 2013
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in germ cell tumor (GCT), sponsored by Michelangelo Foundation. Started May 2013; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT01851200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01851200.